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M.J.W. Koelemay *
Department of Surgery, Academic Medical Center, Amsterdam, The NetherlandsIn this issue of the European Journal of Vascular and
Endovascular Surgery, Brownrigg et al.1 present a detailed
analysis of 30 day outcome in 105 patients with an
abdominal aortic aneurysm (AAA) treated by endovascular
aneurysm sealing (EVAS). EVAS is a novel treatment concept
for patients with an infrarenal AAA, and is aimed at
reducing type II endoleaks and at expanding the options for
endovascular repair in that it has been claimed to have the
potential to treat more patients with unfriendly anatomy
than other devices for EVAR. In this non-consecutive series
of predominantly elective patients with 69% having adverse
neck anatomy, technical success was achieved in 97%, with
four patients having a proximal type I endoleak, which was
resolved by Onyx and coil embolization. Thirty day mortality
was 1%, one patient suddenly died 18 days post-operatively
at home. These excellent results are a reﬂection of the St
George’s Vascular Institute’s (SGVI) wide experience with
AAA repair.
In their paper, the authors share technical difﬁculties and
complications that were encountered during their learning
curve with the device. Of interest, some 62 (59%) of the
patients had adjunctive iliac stenting, which seems to be a
high proportion, and may have been triggered by the au-
thor’s early experience. Three of the ﬁrst 20 patients were
treated post-operatively with additional stents because of
>50% stenosis caused by inadequate stent dilatation or
kinking. The operative technique was adapted by doing
liberal pre-emptive stenting in order to avoid early stent
occlusion. Another technical modiﬁcation was to keep the
balloons inﬂated during polymer curing. Finally, important
lessons were learned from the occurrence of two iatrogenic
ruptures in patients with narrow and calciﬁed common iliac
arteries, which were eventually resolved by insertion of
covered stents.
The current paper is the ﬁrst of a series on early out-
comes of EVAS that can be expected in the near future.
Böckler et al.2 reported similar good results of EVAS in aDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2015.03.024
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http://dx.doi.org/10.1016/j.ejvs.2015.06.022multicenter experience, including some patients from SGVI.
Mortality was zero out of 171 patients, technical success
was 99%. There were ﬁve type Ia and four type 1b endo-
leaks, and 11 (6%) patients had a re-intervention within 30
days, four for device occlusion. The early results of the EVAS
Forward Registry (NCT02018744) with 300 patients and the
EVAS Forward-IDE (investigational device exemption) in the
United States (NCT01726257) with 179 patients are hope-
fully to be published shortly. It is important to realize that
there will be some overlap in patients between the regis-
tries and reports of individual centers, and that results will
be advertised as being achieved in real world patients. Yet,
the results are a representation of real world patients
treated in centers of excellence.
Is the EVAS system going to change the practice of
endovascular aneurysm repair? Although type II endoleaks
occur in less than 1% of patients after EVAS, it is known that
these have limited clinical signiﬁcance in the absence of
aneurysm growth. In a systematic review including 21,744
patients, a type II endoleak was present in 10.2% after
EVAR, with spontaneous resolution in 35.4%.3 Only 14 pa-
tients with an isolated type II endoleak had a ruptured AAA,
six of them without aneurysm sac expansion. A more
important advantage of EVAS might be the expansion of the
indications for endovascular repair in patients with hostile
necks, which is clearly illustrated in the paper by Brownrigg
et al. and to a lesser degree in the Böckler paper. Yet,
pushing the limits may lead to type I endoleaks that may be
difﬁcult to treat after EVAS.
A novel technique introduces new complications and
requires the building of experience with clinical and radio-
logical follow up. AAA sack shrinkage is not to be expected
after EVAS, and it has been noted that the appearance of
type I endoleaks is different from that following conven-
tional EVAR.4,5 The deﬁnitive place of EVAS for AAA exclu-
sion can only be deﬁned after the robustness of the
technique has been demonstrated after sufﬁcient long term
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